Meniere Disease - Pipeline Review, H1 2018

  • ID: 4473130
  • Drug Pipelines
  • 44 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Auris Medical Holding AG
  • Orbis Biosciences Inc
  • Otonomy Inc
  • Quark Pharmaceuticals Inc
  • Sound Pharmaceuticals Inc
  • Synphora AB
  • MORE
Meniere Disease - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Meniere Disease - Pipeline Review, H1 2018, provides an overview of the Meniere Disease (Ear Nose Throat Disorders) pipeline landscape.

Meniere disease is a disorder of the inner ear that causes spontaneous episodes of vertigo. Signs and symptoms of Meniere disease are hearing loss, tinnitus and feeling of fullness in the ear. Causes include allergies, viral infection, head trauma and migraines.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Meniere Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Meniere Disease (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meniere Disease (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 2 respectively.

Meniere Disease (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Meniere Disease (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Meniere Disease (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Meniere Disease (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Meniere Disease (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Meniere Disease (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Auris Medical Holding AG
  • Orbis Biosciences Inc
  • Otonomy Inc
  • Quark Pharmaceuticals Inc
  • Sound Pharmaceuticals Inc
  • Synphora AB
  • MORE
Introduction

Report Coverage

Meniere Disease - Overview

Meniere Disease - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Meniere Disease - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Meniere Disease - Companies Involved in Therapeutics Development

Auris Medical Holding AG

Orbis Biosciences Inc

Otonomy Inc

Quark Pharmaceuticals Inc

Sound Pharmaceuticals Inc

Synphora AB

Meniere Disease - Drug Profiles

betahistine dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

betamethasone valerate ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ebselen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprost - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPHL-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Meniere Disease - Dormant Projects

Meniere Disease - Product Development Milestones

Featured News & Press Releases

Nov 08, 2017: Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX in Patients with Ménière's Disease

Oct 03, 2017: Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Menieres Disease

Aug 30, 2017: Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX in Patients with Menieres Disease

Jun 27, 2017: Sound Pharmaceuticals completes enrollment on Meniere Disease clinical trial

Jun 20, 2017: Otonomy to Host Key Opinion Leader Meeting for Investors on Meniere Disease

Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use

Feb 03, 2017: Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere Disease and Vestibular Vertigo

Jan 19, 2017: Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss

Aug 01, 2016: Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Meniere Disease Patients

Mar 23, 2016: Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Ménière’s Disease

Jan 26, 2016: Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss

Jan 05, 2016: FDA allows Sound Pharmaceuticals to begin Meniere Disease clinical trial

Nov 18, 2015: Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere Disease

Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting

Sep 09, 2015: Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Meniere Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Meniere Disease - Pipeline by Auris Medical Holding AG, H1 2018

Meniere Disease - Pipeline by Orbis Biosciences Inc, H1 2018

Meniere Disease - Pipeline by Otonomy Inc, H1 2018

Meniere Disease - Pipeline by Quark Pharmaceuticals Inc, H1 2018

Meniere Disease - Pipeline by Sound Pharmaceuticals Inc, H1 2018

Meniere Disease - Pipeline by Synphora AB, H1 2018

Meniere Disease - Dormant Projects, H1 2018

List of Figures:

Number of Products under Development for Meniere Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Auris Medical Holding AG
  • Orbis Biosciences Inc
  • Otonomy Inc
  • Quark Pharmaceuticals Inc
  • Sound Pharmaceuticals Inc
  • Synphora AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll